Related Editorial
Pain is a wide-ranging complex medical condition that can be both physically debilitating and mentally destabilizing. Whether acute or chronic, caused by disease, trauma or neural damage, current pain therapeutics primarily rely on a variety of opioid-based pharmacological therapies that have ignited a severe public health crisis. The rampant dependency and abuse of opioid-based drugs has triggered a global quest for effective opioid free medications. Societal demands and sheer market size have bio-pharmaceutical companies searching for solutions to address the critical need for new ways to successfully treat pain. Establishing a new paradigm in pain management solutions, PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF Profile) has undertaken a novel approach in the development of non-addictive analgesics by engineering peptides into efficient pain blockers, eliminating highly addictive opioids. Other companies in the hunt for pain management solutions include AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Nektar Therapeutics (NASDAQ: NKTR), Flexion Therapeutics, Inc. (NASDAQ: FLXN) and Cara Therapeutics (NASDAQ: CARA).
To view the full editorial, visit http://nnw.fm/v7nPC
